Эффективная терапия рака молочной железы препаратами для перорального приема

1. O’Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002; 87: 933–7.
2. Twelves C, Gollins S, Grieve R et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 17: 239–45.
3. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–5.
4. Wojtacki J, Wiraszka R, Rolka-Stempniewicz G et al. Breast cancer patients’ preferences for oral versus intravenous second-line anticancer therapy. Eur J Cancer 2006; 4 (Suppl. 2): 159 (Abstr 381).
5. Fallowfield L, Atkins L, Catt S et al. Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006; 17: 205–10.
6. Kuppens IE, Breedveld P, Beijnen JH et al. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest 2005; 23: 443–64.
7. Blanchette J, Peppas NA. Oral chemotherapeutic delivery: design and cellular response. Ann Biomed Eng 2005; 33: 142–9.
8. Paley M, Love N, Carlson R et al. Preferences for oral and parenteral antitumor therapy: a survey of 260 patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2005; 23 (16S): 619.
9. Catania C, Didier F, Leon ME et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 2005; 92: 265–72.
10. Partridge AH, Avorn J, Wang PS et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94: 652–61.
11. Sharma S. Patient selection for oral chemotherapy. Oncology (Williston Park) 2001; 15 (1 Suppl. 2): 33–5.
12. Damle B, Ravandi F, Kaul S et al. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Clin Cancer Res 2001; 7: 517–23.
13. Bonneterre J, Chevalier B, Focan C et al. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). Ann Oncol 2001; 12: 1683–91.
14. Depierre A, Freyer G, Jassem J et al. Oral vinorelbine: feasibility and safety profile. Ann Oncol 2001; 12: 1677–81.
15. Yabroff KR, Warren JL, Knopf K et al. Estimating patient time costs associated with colorectal cancer care. Med Care 2005; 43: 640–8.
16. Kee F. Patients’ prerogatives and perceptions of benefit. Br Med J 1996; 312: 958–60.
17. Ruland CM. Decision support for patient preference-based care planning. J Am Med Inform Assoc 1999; 6: 304–12.
18. Faithfull S, Deery P. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. Eur J Oncol Nurs 2004; 8 (Suppl. 1): S54–S62.
19. Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004; 8 (Suppl. 1): S41–S53.
20. Decision Resources Survey. Oral chemotherapeutic agents: key success factors and reimbursement issues. A survey of US oncologists and HMO pharmacy directors. June 2005. Roche data on file, 2006.
21. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004; 5: 489–96.
22. Lush RM, McCune JS, Tetteh L et al. The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemother Pharmacol 2005; 56: 578–84.
23. Herben VM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996; 31: 85–102.
24. Hande K, Messenger M, Wagner J et al. Inter- and intra-patient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 1999; 5: 2742–7.
25. Toffoli G, Corona G, Sorio R et al. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol 2001; 52: 511–9.
26. Kruijtzer CM, Beijnen JH, Rosing H et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002; 20: 2943–50.
27. Malingre MM, Beijnen JH, Rosing H et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001; 84: 42–7.
28. Maliepaard M, van Gastelen MA, Tohgo A et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs of the BCRP inhibitor GF120918. Clin Cancer Res 2001; 7: 935–41.
29. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215–37.
30. Rowinsky EK, Lucas VS, Hsieh AL et al. The effects of food and divided dosing on the bioavailability of oral vinorelbine. Cancer Chemother Pharmacol 1996; 39: 9–16.
31. Rough A, MacLeod A, Cassidy J et al. Questionnaire audit assessing compliance in colon cancer patients (pts) taking adjuvant capecitabine (X) as part of the X-ACT trial. Ann Oncol 2004; 15 (Suppl. 3): iii75 (Abstr 283P).
32. Leonard RC, Cameron DA, Anderson A et al. Idarubicin and cyclophosphamide: an active oral chemotherapy regimen for advanced breast cancer. Crit Rev Oncol Hematol 2000; 33: 61–6.
33. Lee CR, Nicholson PW, Souhami RL et al. Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 1992; 10: 1007–13.
34. Lebovits AH, Strain JJ, Schleifer SJ et al. Patient noncompliance with self- administered chemotherapy. Cancer 1990; 65: 17–22.
35. Kirk M, Hudis C. Adherence to prescribed oral medications: understanding the barriers to optimizing hormonal therapy in breast cancer (BC). J Clin Oncol 2006; 24 (18S): 8621.
36. Cassidy J. Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer. Clin Colorectal Cancer 2005; 5 (Suppl. 1): S47–S50.
37. Medicare Benefit Policy Manual, Pub # 100-02 §50.0 Drugs and Biologicals (Rev. 1, 10-01-03).
38. James R, Blanco C, Farina C. Savings in staff time as a result of switching from de Gramont to oral capecitabine for patients with advanced colorectal cancer. Eur J Cancer 2003; 1 (Suppl. 5): S83 (Abstr 271).
39. Twelves C, Boyer M, Findlay M et al. (Xeloda Colorectal Cancer Study Group). Capecitabine (Xeloda) improves medical resource use compared with 5- fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597–604.
40. Jansman FG, Postma MJ, van Hartskamp D et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 2004; 26: 579–89.
41. Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. Br J Cancer 2006; 94: 1122–9.
42. Di Costanzo F, Sobrero A, Twelves C et al. Italian economic evaluation of capecitabine vs. bolus 5-FU/LV as adjuvant chemotherapy for patients with Dukes’ C colon cancer. Ann Oncol 2006; 17 (suppl. 6): 63 (Abstr 130).
43. Garrison L, Patel KK, Sengupta N et al. The cost-effectiveness of capecitabine as adjuvant oral chemotherapy for Dukes’ C colon cancer. Presented at the International Society for Pharmacoeconomics and Outcomes Research 10th International Meeting. Washington DC, USA, 15–18 May, 2005 (Poster PCN7).
44. Husseini F, Douillard J-Y, Ychou M et al. Capecitabine vs. Mayo Clinic and de Gramont 5-FU/LV regimens for stage III colon cancer: cost-effectiveness analysis in the French setting. Ann Oncol 2006; 17 (suppl. 6): 64 (Abstr 133).
45. Bajetta E, Biganzoli L, Carnaghi C et al. Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer. Cancer 1998; 83: 1136–41.
46. Sole? LA, Albanell J, Bellmunt J et al. Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer 1995; 75: 831–5.
47. Daniels M, Diaz-Rubio E, Guillem V et al. Phase II trial of UFT activity in pretreated breast cancer patients. Jpn J Clin Oncol 1993; 23: 363–5.
48. Gupta S, Mauer AM, Ryan CW et al. (University of Chicago Phase II Network). A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. Am J Clin Oncol 2005; 28: 65–9.
49. Rivera E, Sutton L, Colwell B et al. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer. J Clin Oncol 2002; 20: 987–93.
50. Skovsgaard T, Davidson NG, Piccart MJ et al. A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer. Ann Oncol 2001; 12: 1255–7.
51. Smith IE, Johnston SR, O’Brient ME et al. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study. J Clin Oncol 2000; 18: 2378–84.
52. Sato N, Sato Y, Saeki T et al. The cumulative dose of previous treatment does not relate to efficacy of S-1 in patients with taxane-resistant breast cancer. Presented at the San Antonio Breast Cancer Symposium December 8–11, 2004; (Abstr 1078).
53. Saeki T, Takashima S, Sano M et al. A phase II study of S-1 in patients with metastatic breast cancer: a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 2004; 11: 194–202.
54. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485–93.
55. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92: 1759–68.
56. Reichardt P, von Minckwitz G, Thuss-Patience PC et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14: 1227–33.
57. Fumoleau P, Largillier R, Clippe C et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane- pretreated metastatic breast cancer. Eur J Cancer 2004; 40: 536–42.
58. Largillier R, Fumoleau P, Clippe C et al. Capecitabine (X) monotherapy after anthracycline and taxane failure in metastatic breast cancer (MBC): long-term survival data. Ann Oncol 2006; 17 (Suppl. 9): ix74 (Abstr 161P).
59. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792–9.
60. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 2006; 355: 2733–43.
61. Mavroudis D, Ardavanis A, Boukovinas I et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. J Clin Oncol 2006; 24 (18S): 658.
62. Wist EA, Sommer HH, Ostenstad B et al. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 2004; 43: 186–9.
63. Lee SH, Lee J, Park J et al. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 2004; 21: 223–31.
64. Jakob A, Bokemeyer C, Knop S et al. Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation: a phase II study. Anticancer Drugs 2002; 13: 405–10.
65. Talbot DC, Moiseyenko V, Van Belle S et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86: 1367–72.
66. Kurnianda J, Haryadi A, Aryandono T. Efficacy of capecitabine (X) monotherapy in anthracycline-pretreated metastatic breast cancer (MBC): preliminary results of phase II study (experience in a single institution). Ann Oncol 2004; 15 (Suppl. 3): 153P.
67. Cervantes G, Torrecillas L, Erazo A et al. Capecitabine (XELODA) as treatment after failure to taxanes for metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19: 121a (Abstr 469).
68. Stockler MR, Sourjina T, Harvey V et al. A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S278 (Abstr 6066).
69. O’Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247–54.
70. Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23: 2155–61.
71. El-Helw L, Coleman RE. Reduced dose capecitabine is an effective and well- tolerated treatment in patients with metastatic breast cancer. Breast 2005; 14: 368–74.
72. Saeki T, Kimura T, Toi M et al. A pilot phase II study of capecitabine in advanced or recurrent breast cancer. Breast Cancer 2006; 13: 49–57.
73. Zamora P, Alvarez de Mon M, Calvo L et al. Capecitabine (X) in elderly patients with metastatic breast cancer. Ann Oncol 2004; 15 (Suppl. 3): 151P.
74. Freyer G, Delozier T, Lichinister M et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35–40.
75. Amadori D, Koralewski P, Tekiela A. Efficacy and safety of navelbine oral (NVBo) in first line metastatic breast cancer (MBC). Eur J Cancer 2001; 37: 22 (Abstr 713).
76. Frontini L, Ardizzoia A, Giordano M et al. Epirubicin-vinorelbine (EV) intravenous combination followed by oral vinorelbine (VNR) as first-line treatment in advanced breast cancer (ABC) patients: a POLONORD Group study. J Clin Oncol 2005; 23: 70S (Abstr 770).
77. Baweja M, Suman VJ, Fitch TR et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients ?65 years of age: an NCCTG study. Ann Oncol 2006; 17: 623–9.
78. Winer EP, Chu L, Spicer DV. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. Semin Oncol 1995; 22 (Suppl. 5): 72–8.
79. Crivellari D, Lombardi D, Corona G et al. Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. Ann Oncol 2006; 17: 807–12.
80. Freyer G, Lortholary A, Delcambre C et al. Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience. Clin Oncol (R Coll Radiol) 2004; 16: 17–23.
81. Bontenbal M, Planting AS, Verweij J et al. Second-line chemotherapy with long- term low-dose oral etoposide in patients with advanced breast cancer. Breast Cancer Res Treat 1995; 34: 185–9.
82. Saphner T, Weller EA, Tormey DC et al. 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature. Am J Clin Oncol 2000; 23: 258–62.
83. Martin M, Lluch A, Casado A et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994; 12: 986–91.
84. Neskovic-Konstantinovic ZB, Bosnjak SM, Radulovic SS et al. Daily oral etoposide in metastatic breast cancer. Anticancer Drugs 1996; 7: 543–7.
85. Atienza DM, Vogel CL, Trock B et al. Phase II study of oral etoposide for patients with advanced breast cancer. Cancer 1995; 76: 2485–90.
86. Pusztai L, Walters RS, Valero V et al. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol 1998; 21: 442–6.
87. Helgason HH, Kruiktzer CM, Huitema AD et al. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus cyclosporine in anthracycline-pretreated metastatic breast cancer. Br J Cancer 2006; 95: 794–800.
88. Chan SY, Paridaens R, Awada A et al. Phase 2 study of two dose levels of a new oral taxane: DJ-927 in anthracycline pre-treated advanced breast cancer. Ann Oncol 2006; 17 (Suppl. 9): ix137 (Abstr 411P).
89. Vukelja S, O’Shaughnessy J, Campos S et al. Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: phase 2 study results. Proc Am Soc Clin Oncol 2005; 23 (16S): (Abstr 562).
90. Perez EA, Hillman DW, Mailliard JA et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 2004; 22: 2849–55.
91. Mariani P, Moliterni A, Da Prada G et al. A phase II trial of the novel oral camptothecin gimatecan (G) in women with anthracycline (A) and taxane (T) pre-treated advanced breast cancer. J Clin Oncol 2006; 24 (18S): 43s (Abstr 662).
92. Chedid S, Rivera E, Frye DK et al. Minimal clinical benefit of single agent Orathecin (rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemother Pharmacol 2006; 57: 540–4.
93. Trudeau ME, Crump M, Charpentier D et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada–Clinical Trials Group. NCIC-CTG Ann Oncol 2006; 17: 952–6.
94. Sparano JA, Bernado P, Stephenson P et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004; 22: 4683–90.
95. Esteva FJ, Glaspy J, Baidas S et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 2003; 21: 999–1006.
96. Gomez HL, Chavez MA, Doval DC et al. Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer. Proc San Antonio Breast Cancer Symposium 2005 (Abstr 1071).
97. Iwata H, Toi M, Fujiwara Y et al. Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S68 (Abstr 1091).
98. Miller KD, Burstein HJ, Elias AD et al. SU11248 (sunitinib malate) therapy in patients with refractory metastatic breast cancer: preliminary safety and efficacy results from a phase II study. Eur J Cancer 2006; 4: 172.
99. Johnston SR, Hickish T, Ellis P et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003; 21: 2492–9.
100. Moreno-Aspitia A, Hillman DW, Wiesenfeld M et al. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. J Clin Oncol 2006; 24 (18S): 22s (Abstr 577).
101. Bianchi G, Loibl S, Zamagni C et al. A phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer. Eur J Cancer Supplements 2005; 3: 78 (Abstr 276).
102. von Minckwitz G, Jonat W, Fasching P et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005; 89: 165–72.
103. Miller KD, Trigo JM, Wheeler C et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005; 11 (9): 3369–76.
104. Ebi H, Sigeoka Y, Saeki T et al. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5#-deoxy-5- fluorouridine (5-DFUR). Cancer Chemother Pharmacol 2005; 56: 205–11.
105. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274–81.
106. Schull B, Scheithauer W, Kornek GV. Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. Onkologie 2003; 26: 578–80.
107. Silberman G, Gupta S, Berkowitz N et al. Cost-effectiveness of capecitabine, continuous infusion 5-FU, gemcitabine and vinorelbine in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 422a (Abstr 1629).
108. Baran RW, Dupere W, Susan M et al. Clinical and economic outcomes associated with metastatic breast cancer in managedcare populations: capecitabine (Xeloda) versus comparison therapies. Proc Am Soc Clin Oncol 2002; 21: 1942.
109. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nursing 2004; 8: S31–S40.
110. O’Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812–23.
111. Beslija S, Obralic N, Basic H et al. Randomized trial of sequence vs combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2006; 24 (18S): 571.
112. Soto C, Torrecillas L, Reyes S et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomized phase III trial. Proc Am Soc Clin Oncol 2006; 24 (18S): 570.
113. Lueck HJ, von Minckwitz G, Du Bois A et al. Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized multicentre phase III study of the AGO breast cancer study group. J Clin Oncol 2006; 24 (18S): 7s (Abstr 517).
114. Marty M, Fumoleau P, Adenis A et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001; 12: 1643–9.
115. de Jonge ME, Huitema AD, Schellens JH et al. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. Br J Clin Pharmacol 2005; 59: 325–34.
116. Ciardiello F, Troiani T, Caputo F et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006; 94: 1604–9.
117. Kelland LR. Farnesyl transferase inhibitors in the treatment of breast cancer. Expert Opin Investig Drugs 2003; 12: 413–21.
118. Nolе F, Catania C, Sanna G et al. Phase II study of an all-oral regimen combining oral vinorelbine with capecitabine as first-line chemotherapy (CT) of metastatic breast cancer (MBC). Eur J Cancer 5 (4): 218 (Abstr 2114).
119. Tubiana-Mathieu N, Bougnoux P, Becquart D et al. Phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): first results of an international phase II trial. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S280 (Abstr 6072).
120. Lorusso V, Spada M, Giampaglia M et al. Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell’Italia Meridionale). Ann Oncol 2006; 17 (Suppl. 7): vii15–vii17.
121. Gil-Delgado M, Boostan H, Garcia-Giralt E et al. Oral vinorelbine in combination with capecitabine in advanced breast cancer. Proc Am Soc Clin Oncol 2006; 24 (18S): 10586.
122. Finek J, Holubec L, Elgrova L et al. The effect of oral vinorelbine and capecitabine in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2006; 24 (18S): 10605.
123. Pusztai L, Zhen JH, Arun B et al. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 2003; 21: 3454–61.
124. Tong DK, Cheng CW, Ching Chan S et al. Phase II study of an ‘all-oral’ regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer: safety, efficacy and quality of life. Oncology 2005; 68: 520–5.
125. Yoshimoto M, Tada K, Tokudome N et al. The potential for oral combination chemotherapy of 5#-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer. Br J Cancer 2003; 89: 1627–32.
126. Colleoni M, Rocca A, Sandri MT et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13: 73–80.
127. Pavese I, Di Palma M, Capuano G et al. Continuous low dose oral chemotherapy administration in heavily pretreated breast cancer patients. J Clin Oncol 2006; 24 (18S): 10664.
128. Colleoni M, Orlando L, Sanna G et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006; 17: 232–8.
129. Zaniboni A, Bolognesi A, Arnoldi E et al. Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patients. Anticancer Drugs 1998; 9: 295–9.
130. Barnadas A, Mendiola C, Casado A et al. Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study. Eur J Cancer 1997; 33: 312–5.
131. Chow LWC, Sun Y, Jassem J et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S286 (Abstr 6091).
132. Nole F, Catania C, Sanna G et al. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006; 17: 322–9.
133. Delcambre C, Veyret C, Levy C et al. A phase I/II study of capecitabine (X) combined with oral vinorelbine (N) as first- or second-line chemotherapy in patients (pts) with locally advanced breast cancer (MBC). Breast Cancer Res Treat 2005; 24 (1): 67 (Abstr 1081).
134. Kellokumpu-Lehtinen P, Sjostrom J, Lehtinen I et al. A phase I study of an all-oral combination of vinorelbine and capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 2006; 7: 401–5.
135. Cameron DA, Afseth J, Murray E. Oral idarubicin and capecitabine: a dose- finding study confirms this as a safe, effective 1st line therapy for older women with breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl. 1) (Abstr 341).
136. Findlay M, Sharples K, Riley G et al. Capecitabine and oral cyclophosphamide: a novel oral treatment combination for advanced cancer. Asia-Pacific J Clin Oncol 2007; 3: 99–105.
137. Gore L, Holden SN, Cohen RB et al. A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. Ann Oncol 2006; 17: 1709–17.
138. Orlando L, Cardillo A, Rocca A et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006; 17: 961–7.
139. Sawada N, Ishikawa T, Sekiguchi F et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5: 2948–53.
140. Gaui M de F, Amorim G, Arcuri RA et al. A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer. Am J Clin Oncol 2007; 30: 78–81.

И.В.Поддубная, И.В.Колядина

Кафедра онкологии РМАПО, Москва